主页 文献库文献详情
PMID: 42600164 已发表 · aheadofprint 英语

ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

Blood advances ·2026-08-14

Takagi F, Ono T, Takahashi N, Minami Y, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Okada M, Tauchi T, Atsuta Y, Suzuki R, Yamamoto K, Ohtake S, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Kawaguchi T, Kizaki M, Kiyoi H, Miyazaki Y, Matsumura I

摘要

Risk stratification to predict treatment failure in chronic-phase chronic myeloid leukemia (CP-CML) remains an important challenge in the tyrosine kinase inhibitor (TKI) era. We conducted a pooled analysis of 710 newly diagnosed CP-CML patients enrolled in the prospective JALSG CML212 and New TARGET studies, approximately 80% of whom received second-generation TKIs (2G-TKIs) as first-line therapy, to identify predictors of failure-free survival (FFS). In this study, we incorporated the ELN 2025-defined "Warning" category as an initial adverse state in the definition of FFS events and evaluated transitions to "Unfavorable". Within this framework, the EUTOS long-term survival (ELTS) score consistently stratified FFS whether treatment failure included both "Warning" and "Unfavorable" events or was restricted to "Unfavorable". Among patients treated with 2G-TKIs, ELTS demonstrated superior time-dependent discrimination compared with Sokal and remained the baseline predictor of initial treatment failure. Importantly, once "Warning" occurred, baseline ELTS no longer predicted deterioration. Instead, attainment of "Warning" within 6 months after TKI initiation independently predicted transition from "Warning" to "Unfavorable" (HR 7.31, 95% CI 2.94-18.2; p<0.001). These findings distinguish baseline risk from post-milestone disease evolution and support a two-stage risk framework integrating baseline ELTS stratification with "Warning" timing to guide dynamic risk-adapted management in CP-CML.

文献信息
期刊
Blood advances
期刊简称
Blood Adv
ISSN
2473-9537
发表日期
2026-08-14
语言
英语
国家/地区
United States
NLM ID
101698425
分析服务
分析服务

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]